New study


Breast cancer patients who receive radiation therapy often suffer from inflammation linked to the treatment. Austrian Apeiron Biologics AG is now developing a topical superoxide dismutase treatment (APN201) to try to help these women. The Viennese company has begun a further clinical trial at the University of Graz with 20 patients that have received radiation after breast surgery. APN201 was developed by Polymun Scientific AG, another biotech company based in Vienna. Apeiron in­licensed the compound, which has already completed several clinical trials, the most advanced in Phase II. The human enyzme superoxide dismutase is essential for protecting human cells from damage by reactive oxygen species that are created through radiation.



Vienna – Austria-based Intercell AG yesterday announced that its first-in-man trial of the subunit vaccine IV47, designed to prevent infections from the majority of so Streptococcus pneumoniae serotypes, of which there are over...



Vienna – Austrian-based biotech company f-star has closed an EUR8m extension to its Series A financing round. The investment was co-led by MP Healthcare Venture Management and Merck Serono Ventures. Existing investors Atlas...



Vienna – With the naming of Beatrix Karl as the new Minister of Science, the Austrian government is complete. The 42 year-old legal scientist will follow pre­decessor Johannes Hahn, who has accepted a position as European...





Vienna – Austrian vaccine specialist Intercell and GlaxoSmithKline Biologicals SA (GSK) have formed a strategic alliance to commercialise needle-free, patch-based vaccines. The agreement will include Intercell’s candidate vaccine...



Vienna – Austrian firm Intercell AG has initiated a phase II efficacy trial as part of its clinical development program for the investigational travellers’ diarrhoea (TD) vaccine in India. The primary objective of the field trial...



Vienna – Austrian vaccine specialist Intercell AG is to expand the label of its vaccine Ixiaro/JEspect for Japanese encephalitis (JE). On Monday the company announced the start of a clinical phase III study for the travel...

Politics / Law, Miscellaneous, AustriaAustria


Graz – Austria is likely to lead the EU’s efforts to integrate existing national biobanks and associated data throughout Europe into a European biobanking infrastructure. The resource is aimed at reaching critical mass for the...



Vienna – Cardiovascular and inflammatory specialist Fibrex Medical has published positive Phase II results for FX06, a peptide for the treatment of reperfusion injury – damage to heart muscle that results from remedial treatment...

Politics / Law, AustriaAustria


The cultivation of genetically modified organisms (GMOs) in the European Union could soon no longer be decided by scientific facts, but by political preferences. Fourteen member states – among them France, Poland and Portugal –...

Displaying results 31 to 40 out of 116

< Previous 31-40 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%


  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%


  • 4SC1.30 EUR54.8%
  • WILEX3.59 EUR22.9%
  • CO.DON3.15 EUR19.3%


  • MOLOGEN5.08 EUR-35.6%
  • CYTOS1.01 CHF-34.4%
  • BIOTEST79.20 EUR-22.5%


  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%


  • MOLOGEN5.08 EUR-54.7%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 24.04.2015

Current issue

All issues